Blockchain Registration Transaction Record
Clene (NASDAQ: CLNN) Leads the Charge in Treating Neurodegenerative Diseases
Clene (NASDAQ: CLNN) is revolutionizing treatment for neurodegenerative diseases with its lead agent, CNM-Au8, targeting the NAD+ pathway to improve cellular energy production and utilization. Extensive clinical trials have shown CNM-Au8's strong safety profile, positioning Clene as a leader in addressing ALS and MS.
This news matters because Clene's innovative approach with CNM-Au8 has the potential to alter the course of debilitating conditions like ALS and MS. With extensive clinical trials and a strong safety profile, the company is positioned as a leader in addressing neurodegenerative diseases, offering hope to patients and investors alike.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x77be5daeea51041a1ac8a03e224837eb6671e275dec6325b69eecaba47e910e0 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | daveb4Th-1f75ca2e4a469aaf8d989597a09a9b63 |